These results proved that NVP-BEZ235 could exert prominent anti-tumorigenesis efficacy on ccRCC in the relative absence of CHKB-AS1 in vivo (Fig. 3G–I). Here, CHKB is linked to nonpapillary renal cell carcinoma.